Since RDD is a clonal histocyte disorder with mutation in the MAP2K1 and KRAS pathway (16), that are amenable to therapy with MEK inhibitors (17). The gene discussed is KRAS; the disease is sinus histiocytosis with massive lymphadenopathy.